Eugia 3 OAI status may delay ANDA approvals
Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.
AUROPHARMA / Q4-FY24 / risks
Keep the risk register visible.
Aurobindo Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Biosimilar monetization timeline pushed to 2027-2028
Management expects meaningful biosimilar revenue only by 2027-2028, later than some investor expectations.
Pen-G ramp-up complexity may delay benefits
Pen-G fermentation is complex; yield optimization will only be addressed by September, posing execution risk.
Ryzneuta launch in US faces competitive pressure
Management is conservative on Ryzneuta (pegfilgrastim biosimilar) launch, citing multiple competitors and uncertain pricing.